GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » InnoCan Pharma Corp (XCNQ:INNO) » Definitions » EV-to-FCF

InnoCan Pharma (XCNQ:INNO) EV-to-FCF : -13.76 (As of Apr. 28, 2024)


View and export this data going back to 2019. Start your Free Trial

What is InnoCan Pharma EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, InnoCan Pharma's Enterprise Value is C$73.32 Mil. InnoCan Pharma's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was C$-5.33 Mil. Therefore, InnoCan Pharma's EV-to-FCF for today is -13.76.

The historical rank and industry rank for InnoCan Pharma's EV-to-FCF or its related term are showing as below:

XCNQ:INNO' s EV-to-FCF Range Over the Past 10 Years
Min: -17.74   Med: -12.14   Max: -4.92
Current: -13.76

During the past 6 years, the highest EV-to-FCF of InnoCan Pharma was -4.92. The lowest was -17.74. And the median was -12.14.

XCNQ:INNO's EV-to-FCF is ranked worse than
100% of 511 companies
in the Drug Manufacturers industry
Industry Median: 22.05 vs XCNQ:INNO: -13.76

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-04-28), InnoCan Pharma's stock price is C$0.28. InnoCan Pharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was C$-0.023. Therefore, InnoCan Pharma's PE Ratio for today is At Loss.


InnoCan Pharma EV-to-FCF Historical Data

The historical data trend for InnoCan Pharma's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

InnoCan Pharma EV-to-FCF Chart

InnoCan Pharma Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
Get a 7-Day Free Trial -5.72 -12.73 -21.62 -5.65 -14.77

InnoCan Pharma Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -5.65 -7.06 -9.34 -15.01 -14.77

Competitive Comparison of InnoCan Pharma's EV-to-FCF

For the Drug Manufacturers - Specialty & Generic subindustry, InnoCan Pharma's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


InnoCan Pharma's EV-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, InnoCan Pharma's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where InnoCan Pharma's EV-to-FCF falls into.



InnoCan Pharma EV-to-FCF Calculation

InnoCan Pharma's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=73.324/-5.33
=-13.76

InnoCan Pharma's current Enterprise Value is C$73.32 Mil.
InnoCan Pharma's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-5.33 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


InnoCan Pharma  (XCNQ:INNO) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

InnoCan Pharma's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.28/-0.023
=At Loss

InnoCan Pharma's share price for today is C$0.28.
InnoCan Pharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-0.023.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


InnoCan Pharma EV-to-FCF Related Terms

Thank you for viewing the detailed overview of InnoCan Pharma's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


InnoCan Pharma (XCNQ:INNO) Business Description

Traded in Other Exchanges
Address
1015, 926 - 5 Avenue SW, Calgary, AB, CAN, T2P 0N7
InnoCan Pharma Corp is a pharmaceutical tech company that focuses on the development of several drug delivery platforms combining cannabidiol with other pharmaceutical ingredients as well as the development and sale of CBD-integrated pharmaceuticals. Geographically, it derives a majority of its revenue from the United States.

InnoCan Pharma (XCNQ:INNO) Headlines

From GuruFocus

Innocap, Inc. Year End Message To Shareholders

By PRNewswire PRNewswire 12-14-2020

President of Innocap, Inc. is in Singapore

By GlobeNewswire GlobeNewswire 05-03-2018

Innocap, Inc.'s Current Activities

By Marketwired Marketwired 05-24-2018

President of Innocap, Inc. is in Singapore

By Marketwired Marketwired 05-03-2018